Clinical Trial Results:
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
|
Summary
|
|
EudraCT number |
2017-001758-32 |
Trial protocol |
SE GB ES PL FR IT |
Global end of trial date |
27 Jul 2023
|
|
Results information
|
|
Results version number |
v1 |
This version publication date |
17 Dec 2023
|
First version publication date |
17 Dec 2023
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
|
Trial identification
|
|||
Sponsor protocol code |
20140114
|
||
|
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03301857 | ||
WHO universal trial number (UTN) |
- | ||
|
Sponsors
|
|||
Sponsor organisation name |
Amgen Inc.
|
||
Sponsor organisation address |
One Amgen Center Drive, Thousand Oaks, CA, United States,
|
||
Public contact |
IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com
|
||
Scientific contact |
IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com
|
||
|
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
|
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
27 Jul 2023
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
27 Jul 2023
|
||
Was the trial ended prematurely? |
No
|
||
|
General information about the trial
|
|||
Main objective of the trial |
Study 20140114 continued to follow subjects with Giant Cell Tumor of Bone (GCTB) who were treated in Study 20062004 and remained on the study at the completion of Study 20062004 for an additional 5 years on long-term safety follow up.
|
||
Protection of trial subjects |
This study was conducted in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP), Declaration of Helsinki, and applicable national or regional regulations/guidelines. Essential documents will be retained in accordance with ICH GCP. The study sponsor declares that the information provided in this report is an accurate representation of the data captured and analyses performed for this study.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
13 Nov 2017
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety | ||
Long term follow-up duration |
5 Years | ||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
|
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United States: 31
|
||
Country: Number of subjects enrolled |
Italy: 17
|
||
Country: Number of subjects enrolled |
France: 15
|
||
Country: Number of subjects enrolled |
Poland: 8
|
||
Country: Number of subjects enrolled |
Australia: 4
|
||
Country: Number of subjects enrolled |
United Kingdom: 4
|
||
Country: Number of subjects enrolled |
Spain: 3
|
||
Country: Number of subjects enrolled |
Sweden: 3
|
||
Worldwide total number of subjects |
85
|
||
EEA total number of subjects |
46
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
2
|
||
Adults (18-64 years) |
78
|
||
From 65 to 84 years |
4
|
||
85 years and over |
1
|
||
|
|||||||||||||||||||||||||
|
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
Subjects with GCTB were recruited across 8 countries (Australia, Italy, France, Poland, Spain, Sweden, the United Kingdom of Great Britain and Northern Ireland, and the United States) between November 2017 and July 2023. | ||||||||||||||||||||||||
|
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
Study 20140114 was a prospective, multicenter, open label, phase 4 study that provided long term safety follow up for participants who completed Study 20062004 and provided consent to enroll in Study 20140114. | ||||||||||||||||||||||||
|
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
Overall (overall period)
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||
|
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
|
Arm title
|
Exposed to Investigational Product (IP) | ||||||||||||||||||||||||
Arm description |
Participants who received denosumab at the conclusion of Study 20062004 continued receiving denosumab at the current dose (120 mg every 4 weeks [Q4W] subcutaneous injection [SC]) and schedule at the investigator’s discretion. | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
Denosumab
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
XGEVA
|
||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled syringe
|
||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||
Dosage and administration details |
120 mg Q4W SC
|
||||||||||||||||||||||||
|
Arm title
|
Not Exposed to IP | ||||||||||||||||||||||||
Arm description |
Participants who completed denosumab treatment in Study 20062004 and were in the safety follow up at the conclusion of Study 20062004 continued in long term safety follow up in this study (Study 20140114), and did not received denosumab. | ||||||||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Exposed to Investigational Product (IP)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants who received denosumab at the conclusion of Study 20062004 continued receiving denosumab at the current dose (120 mg every 4 weeks [Q4W] subcutaneous injection [SC]) and schedule at the investigator’s discretion. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Not Exposed to IP
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants who completed denosumab treatment in Study 20062004 and were in the safety follow up at the conclusion of Study 20062004 continued in long term safety follow up in this study (Study 20140114), and did not received denosumab. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||
|
End points reporting groups
|
|||
Reporting group title |
Exposed to Investigational Product (IP)
|
||
Reporting group description |
Participants who received denosumab at the conclusion of Study 20062004 continued receiving denosumab at the current dose (120 mg every 4 weeks [Q4W] subcutaneous injection [SC]) and schedule at the investigator’s discretion. | ||
Reporting group title |
Not Exposed to IP
|
||
Reporting group description |
Participants who completed denosumab treatment in Study 20062004 and were in the safety follow up at the conclusion of Study 20062004 continued in long term safety follow up in this study (Study 20140114), and did not received denosumab. | ||
|
||||||||||||||||||||||||||||
End point title |
Number of Participants Experiencing Adverse Events of Interest (EOI) in Participants with GCTB Treated with Denosumab in Study 20062004 [1] | |||||||||||||||||||||||||||
End point description |
EOI assessed in the study were to be assessed for signs and symptoms of the adverse EOI of osteonecrosis of the jaw (ONJ), malignancy (including malignancy in GCTB), atypical femoral fracture (AFF), hypocalcemia, hypercalcemia after treatment discontinuation, pregnancy and lactation (if occurring on treatment or within 5 months of last dose of denosumab).
|
|||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||
End point timeframe |
Up to Approximately 5 Years
|
|||||||||||||||||||||||||||
| Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This endpoint was specified only for the IMP-exposed group. |
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Notes [2] - One pregnancy in female partners of male subjects treated with denosumab was reported |
||||||||||||||||||||||||||||
| No statistical analyses for this end point | ||||||||||||||||||||||||||||
|
|||||||||||||||||||
End point title |
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAE) for Participants who Received Denosumab. [3] | ||||||||||||||||||
End point description |
An adverse event is any untoward medical occurrence in a clinical study subject irrespective of a causal relationship with the study treatment. An adverse event is considered as treatment emergent if the adverse event occurs during the time period from the first dose of investigational product (IP) in this study through last dose of IP plus 30 days. TEAEs related to IP include only TEAEs for which the investigator indicated there was a reasonable possibility they may have been caused by IP.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Up to Approximately 5 Years
|
||||||||||||||||||
| Notes [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was specified only for the IMP-exposed group. |
|||||||||||||||||||
|
|||||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||||
|
|||||||||||||
End point title |
Number of Participants Experiencing Serious Adverse Events | ||||||||||||
End point description |
A Serious Adverse Event is defined as any untoward medical occurrence that meets at least 1 of the following serious criteria:
- Results in death (fatal)
- Immediately life-threatening
- Requires in-patient hospitalization or prolongation of existing hospitalization
- Results in persistent or significant disability/incapacity
- Is a congenital anomaly/birth defect
- Other medically important serious event
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From Date of Signing ICF up to Approximately 5 Years
|
||||||||||||
|
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
|||||||||||||
End point title |
Number of Participants with Disease Progression or Recurrence of GCTB | ||||||||||||
End point description |
Disease progression or recurrence is defined as the best post-baseline response of progressive disease (PD) without any post-baseline complete response (CR) /partial response (PR) /stable disease (SD) or a post-baseline response of PD following a postbaseline CR/PR/SD. PD is defined as the response of progressive disease, locally recurrent disease or distant recurrence as captured in the Disease Status page of the Case Report Form.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to Approximately 5 Years
|
||||||||||||
|
|||||||||||||
| Notes [4] - Number of subjects analyzed: subjects who had at least one post-baseline disease status evaluation. [5] - Number of subjects analyzed: subjects who had at least one post-baseline disease status evaluation. |
|||||||||||||
| No statistical analyses for this end point | |||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
End point title |
Summary of GCTB Interventions | |||||||||||||||||||||||||||||||||||||||
End point description |
Data from the full analysis set (FAS) which included all enrolled subjects (from Study 20062004) who provided informed consent and had a non-missing enrollment date in this study.
|
|||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to Approximately 5 Years
|
|||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| No statistical analyses for this end point | ||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
AE from 1st dose to last dose+30 days in the study. Fatality from 1st dose to end-of-study (EOS) (approximately 5 years); two deaths from not dosed subjects are excluded. Median on IP: 53.4 Months.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
20140114 Primary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
26.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Exposed to IP
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants who received denosumab at the conclusion of Study 20062004 continued receiving denosumab at the current dose (120 mg Q4W SC) and schedule at the investigator’s discretion. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||
Substantial protocol amendments (globally) |
|||
| Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
15 Nov 2017 |
• Clarified guidance to investigators about monitoring subjects for hypercalcemia upon discontinuation or interruption of investigational product.
• Added month 60 to the Schedule of Assessments for clarity. |
||
23 Jan 2018 |
The objective of Study 20140114 was to continue to follow subjects with GCTB who were treated in Study 20062004. A minor language of inclusion criterion 101 was updated to clarify that:
• To be considered potentially eligible for this study, a subject must had participated in the parent 20062004 study and had completed participation in that study, and
• A subject could not be concurrently enrolled to Study 20062004 and Study 20140114; which was not clear according to the original protocol inclusion criterion 101. |
||
23 Aug 2018 |
Schedule of Activities
• Changed the interval between last dose of denosumab and the EOT in person clinic visit.
Study Treatments
• Added detail to denosumab dosing instructions.
Serious Adverse Events
• Clarified procedure for reporting serious adverse events and/or events of interest for subjects who experienced a treatment gap of more than 30 days between the EOS visit of Study 20062004 and signing the ICF for Study 20140114.
Study Rationale
• Clarified that Study 20062004 ended in May 2018, as the study was extended by a year.
• Clarified that subjects with surgically salvageable disease, treatment continued until surgery for complete resection and for approximately 6 months after surgery, as aligned to the 20062004 study.
Overall Design
• Clarified that the EOS visit for all subjects was at 5 years. Cohort A subjects on investigational product had an EOS visit conducted 30 days after the last dose of investigational product (EOT visit) if received investigational product at the 5-year time point.
Lost to Follow up
• Clarified that investigators will not search publicly available records to ascertain survival status when a subject is lost to follow-up.
Discontinuation of Study Treatment
• Clarified that upon discontinuation, subject’s risk for vertebral fragility fractures were evaluated. This language was being added to align language with the core data sheet. |
||
Interruptions (globally) |
|||
| Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
| Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
| None reported | |||
